CCR5-edited RORA-Tscm

About RORABio

RORABio is a private, preclinical biotech spin-out from Case Western Reserve and Emory University, founded in 2021 (operating under a name established in 2004). The company's core asset is the RORA-Tscm platform, a proprietary manufacturing process for a stem-like T-cell population associated with improved clinical outcomes. RORABio is pursuing two primary applications: a bispecific CAR-T for multiple myeloma and a CCR5-edited T-cell therapy for HIV immune reconstitution, with the latter supported by a Gates Foundation grant to Emory. The company is led by a team with deep experience in cell therapy and oncology.

Therapeutic Areas